NRIXNurix Therapeutics, Inc.
Health Care
Operating Lease, Right-of-Use Asset, Amortization Expense revised down 90.8% for Q2 2025
This is the 9th largest revision in NRIX's history.
Operating Lease, Right-of-Use Asset, Amortization Expense
Q2 2025
As reported
$50.2MRestated
$4.6M-90.8%
Verify against SEC filingsShow
As reported$50.2M
Accepted 2025-07-090001549595-25-000095
Restated$4.6M
Accepted 2026-07-090001549595-26-000040
RightOfUseAssetOperating · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get an alert the next time NRIX — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.